
GSK to make redundancies at plant in Stevenage
pharmafile | April 17, 2019 | News story | Research and Development | GSK, GlaxoSmithKline, R&D, redundancies, stevenage
GlaxoSmithKline are set to make redundancies at their site in Stevenage. The move comes as the firm takes “a new approach to research and development,” in focusing more strongly on “transformational medicines.”
As explained by a GSK spokesperson at the Gunnels Wood Road site: “Since we announced our new approach to research and development in 2018, the future direction of our portfolio has become clearer, prioritising innovation and moving towards delivering a pipeline of transformational medicines with a focus on immunology, genetically validated targets, and finding platforms and technologies that amplify our science.”
A company spokesperson said just “a small number of roles” would be directly impacted.
“We have identified where changes are necessary to ensure we can fully support our evolving pipeline priorities. We anticipate a small number of roles will be directly impacted by these changes but continue to expect GSK’s R&D operations to grow overall with increased investment.”
Louis Goss
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

ANGLE’s Parsortix system used in new cancer biology research
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …





